Novel treatment for menopausal symptoms following surgery and adjuvant chemotherapy for premenopausal breast cancer -eficacy and safety in Kampo Medicine

初步研究：表1总结了使用TJ-67治疗的6例患者的特征。他们的绝经症状主要是潮热、出汗等血管舒缩症状，以及睡眠障碍和抑郁等精神症状，但不包括骨骼肌症状，如肩膀僵硬。在6名患者中，有5名患者使用TJ-67治疗后更年期症状明显改善，没有不良反应，但有1名患者(表1中第5位)报告她的症状没有改变。血清E_2水平变化如图1所示。5名患者的血清E_2水平没有变化，但有1名患者(表1中编号6)的血清E_2水平升高，该患者成功地接受了TJ-67治疗。我们报告一位39岁的绝经前乳腺癌患者，出现雌激素缺乏症状，并伴有化疗相关的闭经，并成功地用传统草药(KAMPO)Nyoshinsan/TJ-67治疗。此外，6名有绝经症状的乳腺癌幸存者也接受了TJ-67的治疗，6名患者中有5名患者的病情明显改善，没有不良反应。由于管理乳腺癌幸存者的雌激素缺乏症状仍然存在问题，Nyoshinsan/TJ-67可能是治疗乳腺癌幸存者雌激素缺乏症状的有用和安全的药物。

Preliminary study:Characteristics of 6 patients who were treated with TJ-67 were summarized in Table 1. Their menopausal symptoms were mainly vasomotor symptoms such as hot flushes and sweating, and mental symptoms such as sleeping disorder and depression, but not skeletal muscle symptoms such as shoulder stiffness. In 5 of 6 patients, the treatment of TJ-67 resulted in a noticeable improvement in menopausal symptoms without adverse effects, although one patient (No.5 in Table 1) reported that her symptoms did not change. Changes in the serum levels of E2 are shown in Figure 1. The serum E2 levels in 5 patients did not change, but there was an increase in serum E2 level in one patient (No.6 in Table 1), who was successfully treated with TJ-67. In this patient, the administration of TJ-67 was discontinued and her serum E2 level decreased.Case ReportWe report a 39-year-old woman with premenopausal breast cancer who developed estrogen-deficiency symptoms accompanying chemotherapy- related amenorrhea, and was successfully treated with Nyoshinsan/ TJ-67, traditional herbal medicine ( Kampo ). Furthermore, 6 breast cancer survivors with menopausal symptoms were also treated with TJ-67, and 5 of 6 patients showed noticeable improvement without adverse effects. Since managing estrogen-deficiency symptoms in breast cancer survivors is still problematic, Nyoshinsan/TJ-67 may be a useful and safe agent for estrogen-deficiency symptoms in breast cancer survivors.